Lilly Pursues FDA Approval for Oral GLP-1 Weight Loss Pill
Following a successful phase 3 study, Eli Lilly has officially applied for FDA approval of orforglipron, its oral GLP-1 therapy.
The company announced that its closely monitored obesity pill, orforglipron, aided individuals in maintaining weight loss for as long as a year in a late-stage study. This maintenance occurred after subjects transitioned from injectable GLP-1 medications.
This weight loss pill presents a potential answer to the common problem of weight regain observed when patients stop GLP-1 therapy. Health tracking apps like Shotlee can help monitor weight changes and adherence to treatment plans.
Phase 3 Trial Results
In the pioneering phase 3 trial, individuals who used Lilly's oral GLP-1 therapy for 52 weeks, after having used Zepbound or Novo Nordisk's Wegovy for 72 weeks, largely sustained their weight loss for up to one year.
The primary objective of the orforglipron study was achieved by helping participants, who had previously plateaued on injectables, retain more of their weight loss compared to those on a placebo. This highlights a possible novel application for oral GLP-1 drugs.
The research indicated that patients switching from Wegovy to orforglipron experienced a weight regain of approximately 2 pounds. Those transitioning from Zepbound to orforglipron regained around 11 pounds. This represents an average maintenance rate of 80-95%.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Lilly stated that the safety and tolerability profiles were consistent with prior phase 3 trials of orforglipron. The majority of reported side effects were gastrointestinal in nature and generally ranged from mild to moderate in severity.
Across all study groups, less than 8% of participants stopped treatment due to side effects. Discontinuation rates were slightly higher among those who had taken Lilly's Zepbound before orforglipron, compared to the placebo group.
In its press release, Lilly confirmed the submission of orforglipron for FDA approval as a treatment for obesity.
Given the anticipated increase in competitors within the market, an oral obesity pill would reinforce Lilly's leading position in the weight loss arena.
Earlier in the year, Novo Nordisk, Lilly's primary competitor, submitted its oral version of the blockbuster weight loss drug, Wegovy, to the FDA. Both companies received a fast-track voucher for their respective pills last month under the National Priority program.
Although Novo's oral weight loss drug is projected to gain approval first, both drugs could potentially enter the market around the same time. A decision on Wegovy is expected by the end of this month, while Lilly's orforglipron is anticipated to receive a decision early next year.
